Abstract:Abstract Introduction ADAM28, a member of the ADAM family of metalloproteinases, is over-expressed in several human tumors and is related to cell proliferation and metastasis. Our previous study has demonstrated that the expression level of ADAM28 is significantly elevated in patients with relapsed acute lymphoblastic leukemia, which was associated with poor prognosis. However, the impact of ADAM28 on relapse and the prognosis of patients with AML remains unclear. Aims: To investigate the effect of ADAM28 on the growth and dissemination of leukemia cells and to identify the prognostic significance of ADAM28 levels in patients with AML. Methods and results From 2012-2013, 189 de novo AML patients were prospectively enrolled in this study. The expression of ADAM28 in the leukemic cells of AML patients at diagnosis was significantly higher than that in the donor BM cells. No correlations were found between the expression level of ADAM28 and either FAB classification or cytogenetic risk groups. However, the expression levels of ADAM28 differed significantly between patients suffering a relapse and those remaining in CR. Furthermore, the ADAM28 levels in the cerebrospinal fluid (CSF) of patients with central nervous system leukemia (CNSL) were significantly higher than those in patients without CNSL. These data suggested that ADAM28 levels might be related to the incidence of relapse in patients with AML. We further investigated whether ADAM28 could impact the proliferation, migration and invasiveness of leukemic cells in vitro. Primary AML cells with high ADAM28 expression levels have better proliferation, migration and invasion capacities than those with low ADAM28 expression levels. Knocking out ADAM28with aCRISPR/Cas9 lentivirus significantly inhibited the proliferation, migration and invasion in leukemic cells. The increased expression of ADAM28 lead to more prolific IGFBP-3 degradation and IGF-IR phosphorylation, whereas the ADAM28 knock out cells resulted in significant down-regulation of IGFBP-3 degradation and IGF-IR phosphorylation in leukemic cells. In a xenotransplantation mice model, primary cells with elevated ADAM28 expression have improved engraftment ability in hematopoietic tissue and enhanced dissemination into nonhematopoietic tissue compared with primary cells with lower ADAM28 expression. Blocking ADAM28 expression in leukemic cells ameliorated AML growth and dissemination after xenotransplantation. We then analyzed the prognosis of the cohort of AML patients. Patients were divided into a high expression group and low expression group according to the ADAM28 expression cutoff value based on the status of relapse. The cumulative incidence of relapse (CIR) and overall survival (OS) after a 3-year follow-up were used to evaluate the prognosis. The CIR after 3 years was significantly higher in the ADAM28 high expression group (p<0.0001); the higher CIR translated into a significantly worse OS (p=0.001). Moreover, when separately considering the impact of ADAM28 on prognosis within the risk stratifications, patients with high ADAM28 expression levels had a significantly higher CIR and worse OS in the favorable-risk group but not in the intermediate or poor-risk group. Because the patients with favorable risk were predominantly inclined to chemotherapy, the ADAM28 high expression patients presented a significantly higher CIR and worse OS than the low expression patients in the chemotherapy subgroup, whereas the prognosis did not differ significantly with the ADAM28 expression level in patients receiving HSCT. Conclusion ADAM28 improved the proliferation, migration and invasion of leukemic cells in which the IGF pathway was involved. High expression of ADAM28 enhanced the growth and dissemination of AML in vivo. ADAM28 expression levels also identified a new subgroup at higher risk for relapse and poor prognosis in favorable-risk AML patients, and this subgroup of patients which were allocated to chemotherapy, might benefit more from HSCT. Combining the expression level of ADAM28 with the existing risk stratification standard may be a more precise and preferable approach in predicting therisk of relapse in AML patients. Disclosures No relevant conflicts of interest to declare.

Expression of Adam28 As a Prognostic Biomarker of Survival in Patients with Early-Stage Non-Small Cell Lung Cancer.

Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor

ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study

ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

The Prognostic Value of Expression of Multiple Genes on Resected Non-Small Cell Lung Cancer Tissues

ADAM28 Promotes Tumor Growth and Dissemination of Acute Myeloid Leukemia Through IGFBP-3 Degradation and IGF-I-induced Cell Proliferation.

The Expression Of Adam23 And Its Correlation With Promoter Methylation In Non-Small-Cell Lung Carcinoma

LINC00628 is Differentially Expressed Between Lung Adenocarcinoma and Squamous Cell Carcinoma and is Associated with the Prognosis of NSCLC

Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.

WITHDRAWN: A disintegrin and metalloprotease 8 (ADAM8) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Expression and Clinical Significance of A Disintegrin and Metalloprotease 8 (ADAM8) and Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer

ADAM28 Overexpression Regulated Via the PI3K/Akt Pathway is Associated with Relapse in De Novo Adult B-cell Acute Lymphoblastic Leukemia

A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer

G2 and S phase-expressed protein 1 is a biomarker for poor prognosis in lung adenocarcinoma

The Expression of Stem Cell-Related Indicators As a Prognostic Factor in Human Lung Adenocarcinoma.

Expression of PGAM1 in patients with non-small-cell lung cancer and its correlation with prognosis

Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis

Transcriptional Characterization of Immune Microenvironment and Their Prediction Role for the Prognosis of Local Advanced Lung Adenocarcinoma.

Prognostic Roles Of Pcna Expressions In Non-Small Cell Lung Cancer: A Meta-Analysis